Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Pregnancy and neonatal outcomes of letrozole versus natural cycle frozen embryo transfer of autologous euploid blastocyst. Journal of assisted reproduction and genetics Zhang, W. Y., Gardner, R. M., Johal, J. K., Beshar, I. E., Bavan, B., Milki, A. A., Lathi, R. B., Aghajanova, L. 2023

Abstract

To investigate the pregnancy and neonatal outcomes of letrozole-stimulated frozen embryo transfer (LTZ-FET) cycles compared with natural FET cycles (NC-FET).Our retrospective cohort included all LTZ-FET (n?=?161) and NC-FET (n?=?575) cycles that transferred a single euploid autologous blastocyst from 2016 to 2020 at Stanford Fertility Center. The LTZ-FET protocol entailed 5 mg of daily letrozole for 5 days starting on cycle day 2 or 3. Outcomes were compared using absolute standardized differences (ASD), in which a larger ASD signifies a larger difference. Multivariable regression models adjusted for confounders: maternal age, BMI, nulliparity, embryo grade, race, infertility diagnosis, and endometrial thickness.The demographic and clinical characteristics were overall similar. A greater proportion of the letrozole cohort was multiparous, transferred high-graded embryos, and had ovulatory dysfunction. The cohorts had similar pregnancy rates (67.1% LTZ vs 62.1% NC; aOR 1.31, P?=?0.21) and live birth rates (60.9% LTZ vs 58.6% NC; aOR 1.17, P?=?0.46). LTZ-FET neonates on average were born 5.7 days earlier (P?

View details for DOI 10.1007/s10815-023-02759-2

View details for PubMedID 36849755

View details for PubMedCentralID 8417182